摘要
目的研究通络祛浊方对化学性肝损伤或高脂饲料诱导的大鼠非酒精性单纯性脂肪肝(NAFL)模型的干预效果,并探索作用机制。方法四氯化碳(tetrachloride,CCl4)造模实验设置溶媒组、CCl4模型组和通络祛浊方预防组(简称预防组);高脂饲料造模实验设置空白对照组、高脂饲料模型组和预防组。测定血生化、肝脏脂质含量、细胞色素P450主要亚酶活性,进行组织病理学观察及代谢组学分析等。结果通络祛浊方明显降低两种不同方法诱导的大鼠NAFL模型的肝脏脂质含量,降低肝脏质量及肝脏系数,对血中的甘油三酯(triglyceride,TG)有双向调节作用。CYP酶活性在CCl4模型组有明显降低,并在预防组有明显恢复。通络去浊方干预CCl4诱导的模型主要通过磷脂类物质代谢通道,而高脂饲料模型引起变化的主要代谢物质为游离脂肪酸类。结论通络祛浊方对两种不同因素诱导的大鼠NAFL模型具有较明显的保肝降脂的干预效果,其在不同方法诱导的NAFL中发挥干预作用的主要代谢产物及代谢通路不同。
Aim To investigate the effect of Tongluoquzhuo prescription on the intervention of non-alcoholic simple fatty liver (NAFL) rats established by chemical injury or a high-fat diet. Methods Three testing groups, vehicle group, NAFL group and intervention group were set in the experiment of NAFL rats established by carbon tetrachloride (CCl 4);and those of control group, NAFL group and intervention group were set in the experiment of NAFL rats established by a high-fat diet. Blood biochemical determination, contents of hepatic lipids, CYP enzyme activity, histopathological observation, and metabolomics analysis were measured. Results Tongluoquzhuo prescription reduced the hepatic lipids of NAFL rats established by different methods significantly, lowered liver weight and liver index, and had dual-direction regulation of blood triglyceride (TG). CYP enzyme activity was reduced significantly in NAFL rats established by CCl 4, and raised significantly in intervention group. It may be effected by the pathway of phospholipid to reduce lipid accumulation in the liver of NAFL rats established by CCl 4, while free fatty acid was the most important factor of the interventional effect in NAFL rats established by a high-fat diet. Conclusions Tongluoquzhuo prescription has evident effect of protecting liver and reducing lipids in NAFL rats established by different methods. On the other aspect, It shows difference between the main metabolites and metabolic pathways involved in the intervention of Tongluo turbidity in NAFL established by different methods. It is suggested that different metabolites are required as biomarkers, although different causes can produce similar hepatic steatosis.
作者
金毅
吕爱贞
黄宝明
邢伟
郑又铭
张金龙
杨雯
徐愉林
李静
JIN Yi;LYU Ai-zhen;HUANG Bao-ming;XING Wei;ZHENG You-ming;ZHANG Jin-long;YANG Wen;XU Yu-lin;LI Jing(Shenzhen Institute for Drug Control (Shenzhen Testing Center of Medical Devices), Shenzhen,Guangdong 518057, China;Sunshine Lake Pharma Limited Liability Company (Dept of Pharmacologyin Dong Yang Guang Park), Dongguan, Guangdong 523000, China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2019年第6期863-869,共7页
Chinese Pharmacological Bulletin
基金
深圳市知识创新计划基础研究项目(No JCYJ20160420103948542)
